Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NASDAQ:ARQT NASDAQ:CGEM NASDAQ:KNSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$37.75-1.3%$40.25$26.20▼$63.50$1.76B1.441.17 million shs647,369 shsARQTArcutis Biotherapeutics$14.29-2.0%$14.18$7.86▼$17.75$1.74B1.841.46 million shs1.67 million shsCGEMCullinan Therapeutics$7.67-1.3%$8.10$6.85▼$19.89$458.54M-0.08295,720 shs259,804 shsKNSAKiniksa Pharmaceuticals International$31.98+5.7%$28.38$17.82▼$32.15$2.21B0.14611,693 shs1.07 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics-1.33%-7.52%-14.82%-5.91%-22.48%ARQTArcutis Biotherapeutics-1.99%-3.84%+3.85%-6.23%+41.91%CGEMCullinan Therapeutics-1.29%-6.23%-1.16%-12.74%-60.36%KNSAKiniksa Pharmaceuticals International+5.68%+21.46%+16.55%+15.66%+20.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPGEApogee Therapeutics2.4768 of 5 stars3.50.00.00.03.44.20.0ARQTArcutis Biotherapeutics2.7155 of 5 stars3.43.00.00.02.81.70.6CGEMCullinan Therapeutics1.5964 of 5 stars3.51.00.00.00.61.70.6KNSAKiniksa Pharmaceuticals International3.1499 of 5 stars3.53.00.00.02.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 3.00Buy$99.00162.25% UpsideARQTArcutis Biotherapeutics 2.83Moderate Buy$19.4035.76% UpsideCGEMCullinan Therapeutics 3.00Buy$30.00291.13% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$41.1728.73% UpsideCurrent Analyst Ratings BreakdownLatest CGEM, KNSA, APGE, and ARQT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $54.007/25/2025ARQTArcutis BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$18.007/21/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$36.007/9/2025KNSAKiniksa Pharmaceuticals InternationalWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $42.007/7/2025APGEApogee TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/7/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.007/7/2025APGEApogee TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$100.00 ➝ $115.007/2/2025APGEApogee TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$116.006/11/2025CGEMCullinan TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$22.005/23/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.005/12/2025CGEMCullinan TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $24.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$15.92 per shareN/AARQTArcutis Biotherapeutics$196.54M8.67N/AN/A$1.35 per share10.59CGEMCullinan TherapeuticsN/AN/AN/AN/A$10.14 per shareN/AKNSAKiniksa Pharmaceuticals International$423.24M5.51N/AN/A$6.78 per share4.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$182.15M-$3.60N/AN/AN/AN/A-28.35%-26.98%8/11/2025 (Estimated)ARQTArcutis Biotherapeutics-$140.04M-$1.04N/AN/AN/A-60.95%-80.66%-32.94%8/6/2025 (Estimated)CGEMCullinan Therapeutics-$167.38M-$2.91N/AN/AN/AN/A-29.47%-28.19%8/6/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M$0.04799.70127.92N/A0.90%1.05%0.80%N/ALatest CGEM, KNSA, APGE, and ARQT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CGEMCullinan Therapeutics-$0.7951N/AN/AN/AN/AN/A8/11/2025Q2 2025APGEApogee Therapeutics-$1.08N/AN/AN/AN/AN/A8/6/2025Q2 2025ARQTArcutis Biotherapeutics-$0.19N/AN/AN/A$72.70 millionN/A7/29/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.18$0.23+$0.05$0.23$145.21 million$156.80 million5/12/2025Q1 2025APGEApogee Therapeutics-$1.19-$0.95+$0.24-$0.95N/AN/A5/8/2025Q1 2025CGEMCullinan Therapeutics-$0.78-$0.74+$0.04-$0.74N/AN/A5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/AARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A15.8215.82ARQTArcutis Biotherapeutics0.753.553.37CGEMCullinan TherapeuticsN/A11.6211.62KNSAKiniksa Pharmaceuticals InternationalN/A3.573.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%ARQTArcutis BiotherapeuticsN/ACGEMCullinan Therapeutics86.31%KNSAKiniksa Pharmaceuticals International53.95%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics42.77%ARQTArcutis Biotherapeutics9.40%CGEMCullinan Therapeutics7.16%KNSAKiniksa Pharmaceuticals International53.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9146.05 million26.35 millionOptionableARQTArcutis Biotherapeutics150119.20 million108.00 millionOptionableCGEMCullinan Therapeutics3059.01 million54.79 millionOptionableKNSAKiniksa Pharmaceuticals International22072.97 million33.95 millionOptionableCGEM, KNSA, APGE, and ARQT HeadlinesRecent News About These CompaniesWedbush Research Analysts Lift Earnings Estimates for KNSAAugust 2 at 5:56 AM | marketbeat.comJust The Tonic: This Medical Stock, A Mutual Fund Darling, Tests Entry Amid 58% RunAugust 1 at 1:30 PM | investors.comWhy Kiniksa Pharmaceuticals International, plc (KNSA) Might be Well Poised for a SurgeAugust 1 at 1:20 PM | zacks.comDoes Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect?August 1 at 10:56 AM | zacks.comHere's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep goingAugust 1 at 9:50 AM | zacks.comVictory Capital Management Inc. Takes $1.18 Million Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)July 31 at 3:34 AM | marketbeat.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $54.00 Price Target at Jefferies Financial GroupJuly 30 at 6:56 PM | marketbeat.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 12-Month High Following Better-Than-Expected EarningsJuly 30 at 10:29 AM | marketbeat.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Announces Quarterly Earnings ResultsJuly 30 at 9:18 AM | marketbeat.comKiniksa raises ARCALYST 2025 revenue guidance to $625M-$640M as patient penetration risesJuly 30 at 9:05 AM | msn.comKiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 1-Year High Following Earnings BeatJuly 30 at 2:15 AM | americanbankingnews.comKiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio ExecutionJuly 29, 2025 | finanznachrichten.deKiniksa Pharmaceuticals International, plc 2025 Q2 - Results - Earnings Call PresentationJuly 29, 2025 | seekingalpha.comKiniksa Pharmaceuticals International, plc (KNSA) Q2 2025 Earnings Call TranscriptJuly 29, 2025 | seekingalpha.comKiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue EstimatesJuly 29, 2025 | zacks.comEarnings To Watch: Kiniksa Pharmaceuticals International PLC (KNSA) Reports Q2 2025 ResultJuly 29, 2025 | finance.yahoo.comKiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio ExecutionJuly 29, 2025 | globenewswire.comEarnings Preview: Kiniksa PharmaceuticalsJuly 28, 2025 | benzinga.comKiniksa Pharmaceuticals International, plc Q2 2025 Earnings PreviewJuly 28, 2025 | msn.comKiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Recommendation of "Buy" by BrokeragesJuly 27, 2025 | americanbankingnews.comKiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of "Buy" by AnalystsJuly 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGEM, KNSA, APGE, and ARQT Company DescriptionsApogee Therapeutics NASDAQ:APGE$37.75 -0.51 (-1.33%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$37.73 -0.02 (-0.05%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Arcutis Biotherapeutics NASDAQ:ARQT$14.29 -0.29 (-1.99%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$14.39 +0.10 (+0.67%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Cullinan Therapeutics NASDAQ:CGEM$7.67 -0.10 (-1.29%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.68 +0.00 (+0.07%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Kiniksa Pharmaceuticals International NASDAQ:KNSA$31.98 +1.72 (+5.68%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$32.79 +0.81 (+2.54%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.